Stocks Health care HKPD
NASDAQ · Health careCellyan Biotechnology Co., Ltd (HKPD)
Cellyan Biotechnology Co., Ltd reported revenue of $20.3M in fiscal 2025, up 21.7% from a year earlier. It posted a net loss of $27.1K. Operating cash flow minus capital spending left $499.3K of free cash flow in fiscal 2025. At March 31, 2025 it held $748.7K in cash against $1.9M of debt. Its latest periodic report to the SEC is the annual report (foreign issuer) (20-F) filed on August 7, 2026.
Watch HKPD in 60 secondsWhat Cellyan Biotechnology Co., Ltd does
Cellyan Biotechnology Co., Ltd is registered with the SEC under industry code SIC 5122 (Wholesale-Drugs, Proprietaries & Druggists' Sundries). Its shares trade on NASDAQ under the ticker HKPD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $20.3M | -$27.1K | -$0.00 | $499.3K |
| 2025 | $16.7M | $1.3M | $0.18 | -$447.1K |
| 2023 | $12.6M | $998.2K | $0.15 | $1.6M |
Full financial statements: income, balance sheet and cash flow
Where HKPD ranks in Health care
Latest SEC filings
What Cellyan Biotechnology Co., Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026
- September 23, 2026
- September 10, 2026
- August 13, 2026
- August 7, 2026Annual report (foreign issuer) 20-F · period to March 31, 2026
- July 31, 2026Form NT 20-F filing NT 20-F
- July 16, 2026
- June 12, 2026Form F-3 filing F-3
- March 27, 2026
- March 27, 2026
Who owns HKPD
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Liying Wang13D, may seek influence with 1 related filers | 65% | November 12, 2025 |
| Lap Sun Wong13G, passive | 56.77% | June 3, 2025 |
| Atlantic Health Century International Group13G, passive | 5.62% | June 5, 2025 |
| Pacific Health Century International Group13G, passive | 5.62% | June 5, 2025 |
Largest institutional holders
Insiders
Questions about HKPD
What does Cellyan Biotechnology Co., Ltd do?
Cellyan Biotechnology Co., Ltd is registered with the SEC under industry code SIC 5122 (Wholesale-Drugs, Proprietaries & Druggists' Sundries). Its shares trade on NASDAQ under the ticker HKPD.
Is Cellyan Biotechnology Co., Ltd profitable?
No. In fiscal 2025 it reported a net loss of $27.1K on revenue of $20.3M.
How much revenue does Cellyan Biotechnology Co., Ltd make?
In fiscal 2025 Cellyan Biotechnology Co., Ltd reported revenue of $20.3M. That is 21.7% more than a year earlier.
When did Cellyan Biotechnology Co., Ltd last report?
Its most recent periodic report is the annual report (foreign issuer) (20-F) filed on August 7, 2026. It covers the period to March 31, 2026. Its newest filing of any kind is the foreign issuer update from September 24, 2026.
Similar companies
Compare HKPD with
Follow HKPD
Get an email when Cellyan Biotechnology Co., Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Follow HKPD: get an email when it filesWhere the numbers come from
Financial figures are the values Cellyan Biotechnology Co., Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.